Corgenix Announces Collaboration with SpectraCell Laboratories
Complete the form below to unlock access to ALL audio articles.
Corgenix Medical Corporation has announced its collaboration with SpectraCell Corporation, a Houston, Texas-based specialized clinical testing laboratory company providing cardiovascular and nutritional testing nationwide.
Under terms of the relationship Corgenix' AspirinWorks® product will be used to assess aspirin effect as part of SpectraCell's extensive cardiovascular risk assessment services.
"SpectraCell is increasingly recognized as a major lab in the U.S. for individualized cardiovascular testing and risk assessment. Their unique approach to cardiovascular medicine provides a perfect fit for aspirin effect testing," said Douglass Simpson, Corgenix' President and Chief Executive Officer.
"This new association, combined with their physician-directed sales force, is an important step for Corgenix, and we look forward to a long-term relationship," Simpson added.
The collaboration will allow SpectraCell to take advantage of Corgenix' diagnostic assay that determines the effect of aspirin on platelets in apparently healthy individuals by measuring the level of thromboxane production (aspirin's target).
The higher the levels of thromboxane, the stickier the blood platelets, and the less impact the aspirin is having. Clinical studies suggest that more than 25 percent of all patients taking aspirin are not sufficiently protected from suffering a cardiovascular event.
"This arrangement further expands our functional testing capabilities to include aspirin effect," said Dr. Fred Crawford, VP of Operations and Technical Director at SpectraCell Laboratories. "Partnering with Corgenix helps insure that SpectraCell continues to deliver the most advanced technology and highest quality service to our physician clients nationwide."
